Renaissance Technologies
KLRS

Renaissance Technologies’s Kalaris Therapeutics KLRS Stock Holding History

Renaissance Technologies’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$608K Buy
149,351
+83,200
+126% +$432K ﹤0.01% 2532
2026
Q1 		$382K Sell
66,151
-21,600
-25% -$192K ﹤0.01% 2716
2025
Q4 		$741K Sell
87,751
-25,000
-22% -$160K ﹤0.01% 2413
2025
Q3 		$652K Buy
112,751
+16,000
+17% +$52.9K ﹤0.01% 2684
2025
Q2 		$258K Buy
96,751
+77,500
+403% +$350K ﹤0.01% 3087
2025
Q1 		$155K Buy
19,251
+2,748
+17% +$26.9K ﹤0.01% 3124
2024
Q4 		$159K Sell
16,503
-17,273
-51% -$261K ﹤0.01% 3219
2024
Q3 		$628K Sell
33,776
-624
-2% -$10.9K ﹤0.01% 2682
2024
Q2 		$572K Sell
34,400
-3,056
-8% -$54K ﹤0.01% 2631
2024
Q1 		$650K Buy
37,456
+4,327
+13% +$70.6K ﹤0.01% 2752
2023
Q4 		$518K Buy
33,129
+18,619
+128% +$734K ﹤0.01% 2751
2023
Q3 		$718K Buy
14,510
+1,158
+9% +$78.9K ﹤0.01% 2520
2023
Q2 		$1.04M Sell
13,352
-6,118
-31% -$582K ﹤0.01% 2444
2023
Q1 		$1.76M Buy
19,470
+1,479
+8% +$188K ﹤0.01% 2101
2022
Q4 		$2.12M Buy
17,991
+5,356
+42% +$908K ﹤0.01% 2029
2022
Q3 		$2.29M Sell
12,635
-482
-4% -$75.1K ﹤0.01% 1928
2022
Q2 		$1.18M Buy
13,117
+10,808
+468% +$1.13M ﹤0.01% 2602
2022
Q1 		$358K Buy
+2,309
New +$461K ﹤0.01% 3387
2021
Q3 		– Sell
-1,217
Closed -$553K – 3922
2021
Q2 		$553K Buy
+1,217
New +$628K ﹤0.01% 2924

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Renaissance Technologies's KLRS Position: Q2 2026 in Review

Renaissance Technologies increased its Kalaris Therapeutics (KLRS) stake by 126% in Q2 2026, buying an estimated $432K and bringing the position to 149,351 shares worth $608K. The position accounts for ﹤0.01% of the portfolio, ranked #2532.

Renaissance Technologies first reported a position in KLRS in Q2 2021 and has held it in 19 quarters since. The position peaked at $2.29M in Q3 2022. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Renaissance Technologies held 149,351 shares of Kalaris Therapeutics worth $608K as of Q2 2026.
  • Renaissance Technologies bought 83,200 Kalaris Therapeutics shares in Q2 2026, an estimated $432K.
  • Kalaris Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2532 holding.
  • Renaissance Technologies first reported a position in Kalaris Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Renaissance Technologies's Kalaris Therapeutics position peaked at $2.29M in Q3 2022.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.